RxDoctor Payments DataLook up a doctor →

Atit Shah, MD

Pain Medicine · Sheboygan, WINPI 1487881108

Payments from drug & device makers

$82,689in general payments, 2019–2025

Across 683 payments — averaging $121.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Si-bone, Inc.$55K
  • Abbott$8K
  • Medtronic$4K
  • Spinal Simplicity, LLC$2K
  • SPR Therapeutics, Inc$2K
  • Nevro Corp.$2K
  • plus $9K from 39 others
$465in research payments, 2019–2025

Across 2 payments — averaging $232.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$410
  • Saluda Medical Americas, Inc.$55

What the payments were for

  • Consulting fees$53,04570%
  • Travel & lodging$3,4785%
  • Food & beverage$19,16825%
  • Gifts$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,689 in reported general payments places this provider in the 95th percentile of 82 pain medicine providers in Wisconsin.

See all pain medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$90,327
Medicare patients
187
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl44$34,597
NucyntaTapentadol Hcl27$23,891
Buprenorphine50$14,844
Xtampza ErOxycodone Myristate13$4,299
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen183$3,428
Pregabalin68$1,863
Lidocaine23$1,592
Gabapentin65$1,231
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen52$807
Morphine Sulfate ErMorphine Sulfate22$569
Diclofenac Sodium28$498
Buprenorphine Hcl18$453
Morphine Sulfate19$424
Cyclobenzaprine Hcl29$285
Oxycodone Hcl19$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Xtampza Er$612$62,78684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 pain medicine providers in Wisconsin.

Other pain medicine in Sheboygan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →